GKIM
NVO

GW&K Investment Management’s Novo Nordisk NVO Stock Holding History

GW&K Investment Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29K Buy
601
+1
+0.2% +$43 ﹤0.01% 712
2026
Q1 		$22K Sell
600
-42
-7% -$1.99K ﹤0.01% 742
2025
Q4 		$33K Buy
642
+200
+45% +$10.2K ﹤0.01% 637
2025
Q3 		$25K Hold
442
– – ﹤0.01% 693
2025
Q2 		$31K Hold
442
– – ﹤0.01% 599
2025
Q1 		$31K Sell
442
-239
-35% -$19.7K ﹤0.01% 560
2024
Q4 		$59K Buy
681
+250
+58% +$27K ﹤0.01% 451
2024
Q3 		$51K Hold
431
– – ﹤0.01% 466
2024
Q2 		$62K Sell
431
-6
-1% -$795 ﹤0.01% 424
2024
Q1 		$56K Buy
437
+111
+34% +$13.2K ﹤0.01% 416
2023
Q4 		$34K Hold
326
– – ﹤0.01% 443
2023
Q3 		$30K Sell
326
-50
-13% -$4.41K ﹤0.01% 443
2023
Q2 		$30K Buy
376
+326
+652% +$26.6K ﹤0.01% 431
2023
Q1 		$4K Hold
50
– – ﹤0.01% 425
2022
Q4 		$3K Sell
50
-44
-47% -$2.58K ﹤0.01% 399
2022
Q3 		$5K Hold
94
– – ﹤0.01% 382
2022
Q2 		$5K Hold
94
– – ﹤0.01% 607
2022
Q1 		$5K Sell
94
-23,716
-100% -$1.22M ﹤0.01% 551
2021
Q4 		$1.33M Sell
23,810
-11,492
-33% -$623K 0.01% 318
2021
Q3 		$1.7M Buy
35,302
+468
+1% +$22.6K 0.02% 319
2021
Q2 		$1.46M Buy
34,834
+1,854
+6% +$71.9K 0.01% 325
2021
Q1 		$1.11M Buy
32,980
+4,802
+17% +$171K 0.01% 329
2020
Q4 		$984K Buy
28,178
+2,474
+10% +$85.5K 0.01% 327
2020
Q3 		$892K Buy
25,704
+706
+3% +$23.5K 0.01% 288
2020
Q2 		$818K Buy
24,998
+2,210
+10% +$70.5K 0.01% 285
2020
Q1 		$686K Buy
22,788
+12,712
+126% +$379K 0.01% 276
2019
Q4 		$292K Buy
10,076
+2,678
+36% +$74.2K ﹤0.01% 317
2019
Q3 		$191K Buy
+7,398
New +$187K ﹤0.01% 326

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GW&K Investment Management's NVO Position: Q2 2026 in Review

GW&K Investment Management increased its Novo Nordisk (NVO) stake by 0.17% in Q2 2026, buying an estimated $43 and bringing the position to 601 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #712.

GW&K Investment Management first reported a position in NVO in Q3 2019 and has held it in 28 quarters since. The position peaked at $1.7M in Q3 2021. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • GW&K Investment Management held 601 shares of Novo Nordisk worth $29K as of Q2 2026.
  • GW&K Investment Management bought 1 Novo Nordisk share in Q2 2026, an estimated $43.
  • Novo Nordisk made up ﹤0.01% of GW&K Investment Management's portfolio in Q2 2026, its #712 holding.
  • GW&K Investment Management first reported a position in Novo Nordisk in Q3 2019 and has held it in 28 quarters since.
  • GW&K Investment Management's Novo Nordisk position peaked at $1.7M in Q3 2021.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.